115 related articles for article (PubMed ID: 26994453)
1. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Nguyen E; Coleman CI; Kohn CG; Weeda ER
Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Coleman CI; Freemantle N; Kohn CG
BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Kohn CG; Parker MW; Limone BL; Coleman CI
Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
Ayyasamy L; Bagepally BS
Clin Ther; 2023 May; 45(5):458-465. PubMed ID: 37087299
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
[TBL] [Abstract][Full Text] [Related]
10. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece.
Kourlaba G; Gourzoulidis G; Andrikopoulos G; Tsioufis K; Beletsi A; Maniadakis N
BMC Health Serv Res; 2016 Sep; 16(1):520. PubMed ID: 27678370
[TBL] [Abstract][Full Text] [Related]
14. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
Simpson EL; Duenas A; Holmes MW; Papaioannou D; Chilcott J
Health Technol Assess; 2009 Mar; 13(17):iii, ix-x, 1-154. PubMed ID: 19331797
[TBL] [Abstract][Full Text] [Related]
15. Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
Willis LH; Slentz CA; Johnson JL; Kelly LS; Craig KP; Hoselton AL; Kraus WE
Am J Cardiol; 2019 Sep; 124(5):655-660. PubMed ID: 31296368
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
Rosano GMC; Vitale C; Volterrani M
Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Yuriivna Osovska N; Vitaliivna Kuzminova N
Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine: A Contemporary Review.
Rayner-Hartley E; Sedlak T
J Am Heart Assoc; 2016 Mar; 5(3):e003196. PubMed ID: 26979079
[No Abstract] [Full Text] [Related]
20. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
